Edition:
United States

Biotechnology & Medical Research

Page 1

Pangaea Oncology Renews Contract With AstraZeneca

Tuesday, 16 Jan 2018 03:57am EST

Jan 16 (Reuters) - PANGAEA ONCOLOGY SA ::SAYS SIGNS RENEWAL OF CONTRACT WITH ASTRAZENECA FARMACEUTICA SPAIN FOR ANOTHER 12 MONTHS.WILL CONTINUE TO PROVIDE GENETIC ANALYSIS SERVICES IN LIQUID BIOPSY FOR HOSPITALS IN SPAIN.

Pangaea Oncology Signs Deal For Genetic Analysis In Patients With Cancer In Spain

Tuesday, 9 Jan 2018 04:06am EST

Jan 9 (Reuters) - PANGAEA ONCOLOGY SA ::SIGNS CONTRACT WITH ROCHE DIAGNOSTICS FOR GENETIC ANALYSIS IN PATIENTS WITH CANCER IN SPAIN.AMOUNT OF CONTRACT TO BE BASED ON VOLUME OF SAMPLES RECEIVED BY THE CO.

Xbrane Biopharma Signs Distribution Agreement In South Korea

Tuesday, 19 Dec 2017 07:45am EST

Dec 19 (Reuters) - Xbrane Biopharma Ab ::REG-XBRANE BIOPHARMA SIGNS AGREEMENT WITH BL&H FOR SALES AND MARKETING OF SPHEROTIDE IN SOUTH KOREA.WILL RECEIVE MID-SINGLE DIGIT SEK MLN LICENSE FEE FOR EXCLUSIVE RIGHTS TO SPHEROTIDE IN SOUTH KOREA.XBRANE AND BL&H WILL SHARE PROFITS FROM SALES.TIMING OF LAUNCH IS EXPECTED TO EARLIEST 2019..

Pangen Biotech signs contract worth 4.23 bln won

Monday, 4 Dec 2017 02:09am EST

Dec 4(Reuters) - Pangen Biotech Inc <222110.KQ> ::Says it signed 4.23 billion won contract for cooperation research development and consignment production.

Savara Inc - Development Award Raised to $6.7 Mln - Sec Filing

Thursday, 30 Nov 2017 06:34am EST

Nov 30 (Reuters) - Savara Inc ::SAVARA- ON NOV 28 ENTERED INTO AMENDMENT EFFECTIVE SEPT 30,TO RESEARCH PROGRAM AWARD LETTER AGREEMENT BETWEEN CO, CYSTIC FIBROSIS FOUNDATION THERAPEUTICS.SAVARA INC - UNDER AMENDMENT, AMOUNT OF DEVELOPMENT AWARD AVAILABLE TO SAVARA WAS INCREASED BY $5 MILLION TO AN AGGREGATE OF $6.7 MILLION - SEC FILING.

Savara ‍Received $5 Mln Award For Development Of Aerovanc​

Wednesday, 29 Nov 2017 08:00am EST

Nov 29 (Reuters) - Savara Inc ::SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​.

Celltrion signs contract worth 63.9 bln won

Monday, 27 Nov 2017 02:36am EST

Nov 27 (Reuters) - Celltrion Inc <068270.KQ> ::Says it signed a 63.9 billion won contract with Celltrion Healthcare Co., Ltd to provide biosimilar antibody drug.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary